Identification and Validation of a Six-gene Signature Associated with Glycolysis to Predict the Prognosis of Patients with Cervical Cancer
Overview
Authors
Affiliations
Background: Cervical cancer (CC) is one of the most common gynaecological cancers. The gene signature is believed to be reliable for predicting cancer patient survival. However, there is no relevant study on the relationship between the glycolysis-related gene (GRG) signature and overall survival (OS) of patients with CC.
Methods: We extracted the mRNA expression profiles of 306 tumour and 13 normal tissues from the University of California Santa Cruz (UCSC) Database. Then, we screened out differentially expressed glycolysis-related genes (DEGRGs) among these mRNAs. All patients were randomly divided into training cohort and validation cohort according to the ratio of 7: 3. Next, univariate and multivariate Cox regression analyses were carried out to select the GRG with predictive ability for the prognosis of the training cohort. Additionally, risk score model was constructed and validated it in the validation cohort.
Results: Six mRNAs were obtained that were associated with patient survival. The filtered mRNAs were classified into the protective type (GOT1) and the risk type (HSPA5, ANGPTL4, PFKM, IER3 and PFKFB4). Additionally, by constructing the prognostic risk score model, we found that the OS of the high-risk group was notably poorer, which showed good predictive ability both in training cohort and validation cohort. And the six-gene signature is a prognostic indicator independent of clinicopathological features. Through the verification of PCR, the results showed that compared with the normal cervial tissuses, the expression level of six mRNAs were significantly higher in the CC tissue, which was consistent with our findings.
Conclusions: We constructed a glycolysis-related six-gene signature to predict the prognosis of patients with CC using bioinformatics methods. We provide a thorough comprehension of the effect of glycolysis in patients with CC and provide new targets and ideas for individualized treatment.
Zhang X, Xu W, Wang Z, Liu J, Gong H, Zou W Eur J Med Res. 2024; 29(1):602.
PMID: 39696618 PMC: 11657287. DOI: 10.1186/s40001-024-02191-x.
Fang J, Wang Y, Li C, Liu W, Wang W, Wu X Comput Struct Biotechnol J. 2024; 23:2565-2579.
PMID: 38983650 PMC: 11231957. DOI: 10.1016/j.csbj.2024.06.007.
Yuan L, Wang Y, Yu M, Feng Z, Ci M, Wang C iScience. 2024; 27(6):110112.
PMID: 38947495 PMC: 11214327. DOI: 10.1016/j.isci.2024.110112.
Predictive Value and Immunological Role of the HSPA5 Gene in Cervical Cancer.
Bai Y, Miao Y, Wang J, Gan J, Feng J Biochem Genet. 2024; .
PMID: 38584219 DOI: 10.1007/s10528-024-10782-w.
Increased Gene Expression of Is Associated with Poor Prognosis in Cervical Cancer.
Parida P, Lewis S, Sharan K, Kamal M, Kumar N, Godkhindi V Cells. 2023; 12(21).
PMID: 37947608 PMC: 10649411. DOI: 10.3390/cells12212530.